Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Revenue: 2011-2025

Historic Revenue for Fennec Pharmaceuticals (FENC) over the last 5 years, with Sep 2025 value amounting to $12.5 million.

  • Fennec Pharmaceuticals' Revenue rose 78.69% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.8 million, marking a year-over-year decrease of 21.39%. This contributed to the annual value of $47.5 million for FY2024, which is 123.69% up from last year.
  • Per Fennec Pharmaceuticals' latest filing, its Revenue stood at $12.5 million for Q3 2025, which was up 29.11% from $9.7 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Revenue ranged from a high of $25.4 million in Q1 2024 and a low of -$914,000 during Q4 2022.
  • Its 3-year average for Revenue is $9.1 million, with a median of $7.9 million in 2024.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Revenue tumbled by 1,350.00% in 2022, and later surged by 5,933.33% in 2023.
  • Fennec Pharmaceuticals' Revenue (Quarterly) stood at -$55,000 in 2021, then tumbled by 116.36% to -$914,000 in 2022, then surged by 1,165.10% to $9.7 million in 2023, then declined by 18.59% to $7.9 million in 2024, then soared by 78.69% to $12.5 million in 2025.
  • Its Revenue was $12.5 million in Q3 2025, compared to $9.7 million in Q2 2025 and $8.8 million in Q1 2025.